Terms: = Lung cancer AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC
129 results:
1. Clinicopathological, metastatic and prognostic features of stage IV esophageal adenocarcinoma versus squamous cell carcinoma: a SEER database analysis.
Pan L; Zhang Y; Gao Y; Qiu J
Chin Clin Oncol; 2024 Feb; 13(1):2. PubMed ID: 38372056
[TBL] [Abstract] [Full Text] [Related]
2. Incidentally Detected lung cancer in Persons Too Young or Too Old for lung cancer Screening in a Mississippi Delta Cohort.
Liao W; Fehnel C; Goss J; Shepherd CJ; Qureshi T; Matthews AT; Ray MA; Faris NR; Pinsky PF; Smeltzer MP; Osarogiagbon RU
J Thorac Oncol; 2024 Apr; 19(4):589-600. PubMed ID: 37984678
[TBL] [Abstract] [Full Text] [Related]
3. A novel necroptosis related gene signature and regulatory network for overall survival prediction in lung adenocarcinoma.
Wang G; Liu X; Liu H; Zhang X; Shao Y; Jia X
Sci Rep; 2023 Sep; 13(1):15345. PubMed ID: 37714937
[TBL] [Abstract] [Full Text] [Related]
4. Neoplastic Progression of Barrett's Esophagus Among Organ Transplant Recipients: a Retrospective Cohort Study.
Patel V; Sanaka MR; Qin Y; McMichael J; Bena J; Beveridge C; Barron J; Raja S; Modaresi Esfeh J; Thota PN
J Gastrointest Surg; 2023 Sep; 27(9):1785-1793. PubMed ID: 37268829
[TBL] [Abstract] [Full Text] [Related]
5. Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.
Raza A; Mohsen R; Kanbour A; Zar Gul AR; Philip A; Vijayakumar S; Hydrose S; Prabhu KS; Al-Suwaidi AK; Inchakalody VP; Merhi M; Abo El-Ella DM; Tauro MA; Akbar S; Al-Bozom I; Abualainin W; Al-Abdulla R; Sirriya SA; Hassnad S; Uddin S; Mohamed Ibrahim MI; Al Homsi U; Demime S
Front Immunol; 2023; 14():1157100. PubMed ID: 37256148
[TBL] [Abstract] [Full Text] [Related]
6. Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma.
Kumar S; Zhao J; Talluri S; Buon L; Mu S; Potluri LB; Liao C; Shi J; Chakraborty C; Gonzalez GB; Tai YT; Patel J; Pal J; Mashimo H; Samur MK; Munshi NC; Shammas MA
Gastroenterology; 2023 Aug; 165(2):357-373. PubMed ID: 37178737
[TBL] [Abstract] [Full Text] [Related]
7. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
[TBL] [Abstract] [Full Text] [Related]
8. Engineered APOBEC3C Sequencing Enables Bisulfite-Free and Direct Detection of DNA Methylation at a Single-Base Resolution.
Wang M; Xie NB; Chen KK; Ji TT; Xiong J; Guo X; Yu SY; Tang F; Xie C; Feng YQ; Yuan BF
Anal Chem; 2023 Jan; 95(2):1556-1565. PubMed ID: 36563112
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.
Ho HL; Jiang Y; Chiang CL; Karwowska S; Yerram R; Sharma K; Scudder S; Chiu CH; Tsai CM; Palma JF; Sharma A; Chou TY
PLoS One; 2022; 17(4):e0267362. PubMed ID: 35482671
[TBL] [Abstract] [Full Text] [Related]
10. The Survival Impact of Second Primary lung cancer in Patients With lung cancer.
Choi E; Luo SJ; Aredo JV; Backhus LM; Wilkens LR; Su CC; Neal JW; Le Marchand L; Cheng I; Wakelee HA; Han SS
J Natl Cancer Inst; 2022 Apr; 114(4):618-625. PubMed ID: 34893871
[TBL] [Abstract] [Full Text] [Related]
11. Development of a prognostic signature of patients with esophagus adenocarcinoma by using immune-related genes.
Zhang X; Yang L; Kong M; Ma J; Wei Y
BMC Bioinformatics; 2021 Nov; 22(1):536. PubMed ID: 34724890
[TBL] [Abstract] [Full Text] [Related]
12. Downregulation of m
Wang J; Tan L; Jia B; Yu X; Yao R; OUYang N; Yu X; Cao X; Tong J; Chen T; Chen R; Li J
Int J Biol Sci; 2021; 17(10):2633-2651. PubMed ID: 34326699
[TBL] [Abstract] [Full Text] [Related]
13. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.
Lam TC; Tsang KC; Choi HC; Lee VH; Lam KO; Chiang CL; So TH; Chan WW; Nyaw SF; Lim F; Lau JO; Chik J; Kong FM; Lee AW
Lung Cancer; 2021 Sep; 159():18-26. PubMed ID: 34303276
[TBL] [Abstract] [Full Text] [Related]
14. Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes.
Li R; Yang Z; Shao F; Cheng H; Wen Y; Sun S; Guo W; Li Z; Zhang F; Xue L; Bi N; Wang J; Sun Y; Li Y; Tan F; Xue Q; Gao S; Shi S; Gao Y; He J
Nat Commun; 2021 Jun; 12(1):3785. PubMed ID: 34145257
[TBL] [Abstract] [Full Text] [Related]
15. Therapeutic Synergy in Esophageal cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
Surman DR; Xu Y; Lee MJ; Trepel J; Brown K; Ramineni M; Splawn TG; Diggs LP; Hodges HC; Davis JL; Lee HS; Burt BM; Ripley RT
Mol Cancer Ther; 2021 Aug; 20(8):1469-1480. PubMed ID: 34088830
[TBL] [Abstract] [Full Text] [Related]
16. STAT3/miR-135b/NF-κB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer.
Zhao J; Wang X; Mi Z; Jiang X; Sun L; Zheng B; Wang J; Meng M; Zhang L; Wang Z; Song J; Yuan Z; Wu Z
Cell Death Dis; 2021 May; 12(5):493. PubMed ID: 33990540
[TBL] [Abstract] [Full Text] [Related]
17. Geraniol exerts its antiproliferative action by modulating molecular targets in lung and skin carcinoma cells.
Fatima K; Wani ZA; Meena A; Luqman S
Phytother Res; 2021 Jul; 35(7):3861-3874. PubMed ID: 33826182
[TBL] [Abstract] [Full Text] [Related]
18. MicroRNA-370-3p shuttled by breast cancer cell-derived extracellular vesicles induces fibroblast activation through the cyld/Nf-κB axis to promote breast cancer progression.
Ren Z; Lv M; Yu Q; Bao J; Lou K; Li X
FASEB J; 2021 Mar; 35(3):e21383. PubMed ID: 33629796
[TBL] [Abstract] [Full Text] [Related]
19. MiR-587 acts as an oncogene in non-small-cell lung carcinoma via reducing cyld expression.
Li XJ; Chen LW; Gao P; Jia YJ
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12741-12747. PubMed ID: 33378022
[TBL] [Abstract] [Full Text] [Related]
20. Optimization of Immunophenotypic Panel to Differentiate Upper From Lower Gastrointestinal Adenocarcinomas: Analysis of New and Traditional Markers.
Chauhan A; Sanchez-Avila M; Manivel J; Dachel S; Larson W; Hanson B; Gravely A; Mesa H
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):13-19. PubMed ID: 33295746
[TBL] [Abstract] [Full Text] [Related]
[Next]
